Abstract
Clinical studies have confirmed the FOLFIRINOX regimen (oxaliplatin+ irinotecan+ fluo-rouracil+ leucovorin) is an effective regimen for advanced pancreatic cancer patients with good performance status. Current clinical studies on FOLFIRINOX regimen mainly include neoadjuvant therapy for unresectable and borderline resectable pancreatic cancer and first-line therapy for locally advanced pancreatic cancer and metastatic pancreatic cancer, which improved patient′s surgical resection opportunities and survival. In addition, the toxicity, safety of FOLFIRINOX regimen and effective population selection for FOLFIRINOX regimen are also the problems concerned by researchers. Key words: Pancreatic neoplasms; Drug therapy; FOLFIRINOX regimen
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
